Dissociative states in borderline personality disorder and their relationships to psychotropic medication

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10385129" target="_blank" >RIV/00216208:11110/18:10385129 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14740/18:00106588

Výsledek na webu

<a href="https://doi.org/10.2147/NDT.S179091" target="_blank" >https://doi.org/10.2147/NDT.S179091</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/NDT.S179091" target="_blank" >10.2147/NDT.S179091</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Dissociative states in borderline personality disorder and their relationships to psychotropic medication

Popis výsledku v původním jazyce

Background: According to recent data, dissociation may play an important role in borderline personality disorder (BPD), nevertheless specific influences of psychotropic medication on dissociative symptoms in BPD and their therapeutic indications are largely unknown. The purpose of this study was to assess relationships of dissociative symptoms in BPD patients with levels of psychotropic medication and compare these results with a subgroup of patients with schizophrenia. Materials and methods: In this study, we investigated 52 BPD patients and compared the results with a control group of 36 schizophrenia patients. In all participants, we assessed actual day doses of antipsychotic medication in chlorpromazine equivalents and antidepressant medication in fluoxetine equivalents. Dissociative symptoms were measured by Dissociative Experiences Scale (DES), and other psychopathological symptoms were measured using Health of the Nation Outcome Scales. Results: Results indicate that dissociative symptoms measured by DES were significantly correlated with antipsychotic medication (Spearman R=0.45, P&lt;0.01) in chlorpromazine equivalents and antidepressant medication in fluoxetine equivalents (0.36, P&lt;0.01). These relationships between medication and dissociative symptoms were not found in the control group of schizophrenia patients. Conclusion: The results suggest that levels of antipsychotic medication and antidepressant medication are significantly associated with dissociative symptoms in BPD but not in schizophrenia.

Název v anglickém jazyce

Dissociative states in borderline personality disorder and their relationships to psychotropic medication

Popis výsledku anglicky

Background: According to recent data, dissociation may play an important role in borderline personality disorder (BPD), nevertheless specific influences of psychotropic medication on dissociative symptoms in BPD and their therapeutic indications are largely unknown. The purpose of this study was to assess relationships of dissociative symptoms in BPD patients with levels of psychotropic medication and compare these results with a subgroup of patients with schizophrenia. Materials and methods: In this study, we investigated 52 BPD patients and compared the results with a control group of 36 schizophrenia patients. In all participants, we assessed actual day doses of antipsychotic medication in chlorpromazine equivalents and antidepressant medication in fluoxetine equivalents. Dissociative symptoms were measured by Dissociative Experiences Scale (DES), and other psychopathological symptoms were measured using Health of the Nation Outcome Scales. Results: Results indicate that dissociative symptoms measured by DES were significantly correlated with antipsychotic medication (Spearman R=0.45, P&lt;0.01) in chlorpromazine equivalents and antidepressant medication in fluoxetine equivalents (0.36, P&lt;0.01). These relationships between medication and dissociative symptoms were not found in the control group of schizophrenia patients. Conclusion: The results suggest that levels of antipsychotic medication and antidepressant medication are significantly associated with dissociative symptoms in BPD but not in schizophrenia.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuropsychiatric Disease and Treatment

ISSN

1178-2021

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

November

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

5

Strana od-do

3253-3257

Kód UT WoS článku

000451245400002

EID výsledku v databázi Scopus

2-s2.0-85057541219